Novo Nordisk A/S - Reduction of the share capital
24-04-19 kl. 24/4 2019 18:26 | Novo Nordisk A/s 46,52 (+0,65%)
Se flere nyheder om Novo Nordisk A/s
Bagsværd, Denmark, 24 April 2019 - At Novo Nordisk's Annual General Meeting on 21 March 2019, it was decided to reduce the company's B share capital from DKK 382,512,800 to DKK 372,512,800 by cancellation of part of the company's portfolio of own B shares equal to a nominal value of DKK 10,000,000 divided into 50,000,000 B shares of DKK 0.20 each.
Today, Novo Nordisk has registered the implementation of the reduction of the share capital with the Danish Business Authority and cancelled B shares at a nominal value of DKK 10,000,000. After the reduction of the share capital, the company's share capital is nominally DKK 480,000,000, which is divided into an A share capital of nominally DKK 107,487,200 and a B share capital of nominally DKK 372,512,800.
The reduction of the share capital will not affect Novo Nordisk's share repurchase programme which will continue as previously announced.
Further information
| Media: | ||
| Anne Margrethe Hauge | +45 4442 3450 | [email protected] |
| Ken Inchausti (US) | +1 609 786 8316 | [email protected] |
| Investors: | ||
| Peter Hugreffe Ankersen | +45 3075 9085 | [email protected] |
| Valdemar Borum Svarrer | +45 3079 0301 | [email protected] |
| Ann Søndermølle Rendbæk | +45 3075 2253 | [email protected] |
| Kristoffer Due Berg (US) | +1 609 235 2989 | [email protected] |
Company announcement no. 24 / 2019
20190424 - Capital Reduction
Apr 24, 2019
Skriv en kommentarer til denne artikel:
Send kommentar
| PRIS | 46,52 |
|---|---|
| ÆNDRING | +0,30 (+0,65%) |
| ÅBEN | 46,47 |
| SIDSTE LUK | 0,00 |
| DEBAT | - |
 |
